Literature DB >> 2211701

Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.

G Jansen1, G R Westerhof, M J Jarmuszewski, I Kathmann, G Rijksen, J H Schornagel.   

Abstract

This study reports the isolation and characterization of a variant of the human CCRF-CEM leukemia cell line that overproduces the carrier protein responsible for the uptake of reduced folates and the folate analogue methotrexate. The variant was obtained by adapting CCRF-CEM cells for prolonged times to stepwise decreasing concentrations of 5-formyltetrahydrofolate as the sole folate source in the cell culture medium. From cells that were grown on less than 1 nM 5-formyl-tetrahydrofolate, a variant (CEM-7A) was isolated exhibiting a 95-fold increased Vmax for [3H]methotrexate influx compared to parental CCRF-CEM cells. The values for influx Km, efflux t0.5, and Ki for inhibition by other folate (analogue) compounds were unchanged. Affinity labeling of the carrier with an N-hydroxysuccinimide ester of [3H]methotrexate demonstrate an approximately 30-fold increased incorporation of [3H] methotrexate in CEM-7A cells. This suggests that the up-regulation of [3H]methotrexate influx is not only due to an increased amount of carrier protein, but also to an increased rate of carrier translocation or an improved cooperativity between carrier protein molecules. Incubation for 1 h at 37 degrees C of CEM-7A cells with a concentration of 5-formyltetrahydrofolate or 5-methyltetrahydrofolate in the physiological range (25 nM) resulted in a 7-fold decline in [3H]methotrexate influx. This down-regulation during incubations with 5-formyltetrahydrofolate or 5-methyltetrahydrofolate could be prevented by either the addition of 10-25 nM of the lipophilic antifolate trimetrexate or by preincubating CEM-7A cells with 25 nM methotrexate. The down-regulatory effect was specifically induced by reduced folates since incubation of CEM-7A cells with 25 nM of either methotrexate, 10-ethyl-10-deazaaminopterin, aminopterin, or folic acid, or a mixture of purines and thymidine, had no effect on [3H]methotrexate influx. Similarly, these down-regulatory effects on [3H]methotrexate transport by 5-formyltetrahydrofolate, and its reversal by trimetrexate or methotrexate, were also observed, though to a lower extent, for parental CCRF-CEM cells grown in folate-depleted medium rather than in standard medium containing high folate concentrations. These results indicate that mediation of reduced folate/methotrexate transport can occur at reduced folate concentrations in the physiological range, and suggest that the intracellular folate content may be a critical determinant in the regulation of methotrexate transport.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211701

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter.

Authors:  Johnathan R Whetstine; Robin M Flatley; Larry H Matherly
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

2.  Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter.

Authors:  Larry H Matherly; Zhanjun Hou
Journal:  Vitam Horm       Date:  2008       Impact factor: 3.421

Review 3.  Mechanisms of membrane transport of folates into cells and across epithelia.

Authors:  Rongbao Zhao; Ndeye Diop-Bove; Michele Visentin; I David Goldman
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

4.  SLC19A1 Is an Importer of the Immunotransmitter cGAMP.

Authors:  Christopher Ritchie; Anthony F Cordova; Gaelen T Hess; Michael C Bassik; Lingyin Li
Journal:  Mol Cell       Date:  2019-05-21       Impact factor: 17.970

5.  Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.

Authors:  G Jansen; G R Westerhof; I Kathmann; G Rijksen; J H Schornagel
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 6.  The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.

Authors:  Larry H Matherly; Mike R Wilson; Zhanjun Hou
Journal:  Drug Metab Dispos       Date:  2014-01-06       Impact factor: 3.922

7.  Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates.

Authors:  K N Chung; Y Saikawa; T H Paik; K H Dixon; T Mulligan; K H Cowan; P C Elwood
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines.

Authors:  Lilah Rothem; Ilan Ifergan; Yotam Kaufman; David G Priest; Gerrit Jansen; Yehuda G Assaraf
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

9.  The effect of folate on the methotrexate/indomethacin interaction in a murine cancer cell line.

Authors:  S J Hollingsworth; E M Anderson; A Bennett
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

10.  The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis.

Authors:  Ilan Ifergan; Gerrit Jansen; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.